Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Technical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus Pharma

PR Newswire February 28, 2017

Aurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin

Business Wire February 14, 2017

Aurinia’s New CEO, Richard Glickman, to Present at Leerink Partners 6th Annual Global Healthcare Conference

Business Wire February 10, 2017

Aurinia Announces Appointment of Company Founder, Dr. Richard M. Glickman, as its New Chief Executive Officer

Business Wire February 6, 2017

The Biotech Market Grows as Demand for New Therapeutics Increases

PR Newswire February 6, 2017

Aurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial

Business Wire January 27, 2017

Aurinia Pharmaceuticals to Participate in Upcoming Conferences

Business Wire January 26, 2017

18 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  December 30, 2016

Aurinia Closes US$28 Million Financing

Business Wire December 28, 2016

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  December 22, 2016

Aurinia Announces US$25.0 Million Bought Deal Financing

Business Wire December 22, 2016

Aurinia Announces Long-Term Manufacturing Collaboration Agreement with Lonza for Clinical and Commercial Supply of Voclosporin

Business Wire December 19, 2016

20 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  December 14, 2016

20 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  December 13, 2016

Aurinia Confirms Receipt of FDA End of Phase 2 Meeting Minutes

Business Wire December 13, 2016

Aurinia Announces Appointment of Biotech Industry Leader Jeffry Randall to its Board of Directors and Audit Committee

Business Wire December 12, 2016

Technical Reports on Biotech Equities -- Aurinia Pharma, Threshold Pharma, Regeneron Pharma, and INSYS Therapeutics

PR Newswire December 8, 2016

Aurinia Highlights Renal Function Data from Global Phase IIb AURA Study of Voclosporin for Lupus Nephritis at American Society of Nephrology Kidney Week 2016

Business Wire November 21, 2016

Biotech Stocks Forge Ahead With Confidence on This Week's Healthy Biotech Rally

PR Newswire November 17, 2016

Aurinia Highlights Speed of Remission from Global Phase IIb AURA Study of Voclosporin in Lupus Nephritis at 2016 American College of Rheumatology Annual Meeting

Business Wire November 16, 2016